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The generalized use of physical methods, X-ray diffraction and Fourier transform infrared
spectroscopy (FTIR) decisively improved urinary stone analysis by allowing to accurately
identify the chemical nature, crystalline phases and relative proportions of stone con-
stituents. Such compositional analysis is sufﬁcient to identify stone diseases involving a
single speciﬁc component such as cystine, 2,8-dihydroxyadenine (DHA), struvite, uric acid,
ammonium hydrogen urate or a drug. However, for common calcium nephrolithiasis,
which represents by far the largest part of urinary stones throughout the world, the simple
identiﬁcation of calcium oxalate (CaOx) and/or calcium phosphate (CaP) as constituents
provides incomplete etiologic information because a same elemental stone composition
may result from different lithogenic processes.
A more comprehensive method combining careful morphologic examination of the surface
and the section of stones with detailed FTIR analysis of the nature, location, crystalline
phases and a respective proportion of stone constituents, therefore termed ‘morpho-
constitutional’ analysis, as used in our laboratory for four decades provides more complete
etiologic information. In common idiopathic CaOx nephrolithiasis, the predominance of
the monohydrate form (COM) was shown to be associated with elevated urine Ox con-
centration, whereas the dihydrate form (COD) was associated with hypercalciuria, thus
orienting dietary and/or pharmacological intervention. A major contribution of the method
is to immediately orient the diagnosis of rare, but severe, diseases leading to a loss of renal
function, when stone analysis reveals a peculiar morphology of common constituents. The
most salient examples are the type Ic morphology of COM stones, pathognomonic of
primary hyperoxaluria, type Ie morphology, which is highly suggestive of absorptive
hyperoxaluria as seen in inﬂammatory bowel diseases and pathologies inducing steator-
rhea, type IIId morphology of ammonium urate stones, which orientates towards chronic
diarrhea with dietary imbalance and loss of electrolytes, and type IVa2 morphology of
carbapatite, speciﬁc of distal renal tubular acidosis of congenital or acquired origin, andrvice des Explorations Fonctionnelles, 4 Rue de la Chine, 75970 Paris Cedex 20, France.
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M. Daudon et al. / C. R. Chimie 19 (2016) 1470e1491 1471distinctive aspect of 2,8-DHA stones. In conclusion, the proposed morpho-constitutional
method should be recommended for routine stone analysis, inasmuch as it is simple,
rapid, reliable, clinically relevant and cost-effective.
© 2016 Académie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The analysis of urinary stones is currently performed by
physical methods, namely X-ray diffraction (XRD) or Four-
ier transform infrared spectroscopy (FTIR). These methods
allow to identify the chemical nature of stone constituents
and to provide semi-quantitative evaluation of their
respective proportions within a calculus. This global anal-
ysis classiﬁes calculi as mainly composed of calcium oxalate
(CaOx), calcium phosphate (CaP), uric acid, struvite and
cystine, which together represent approximately 98% of all
urinary stones, with calcium stones accounting for more
than 80% of the total [1]. Although they also allow to
identify the crystalline phases of CaOx, namely CaOx
monohydrate (COM) or whewellite and CaOx dihydrate
(COD) or weddellite, this distinction is not provided inmost
laboratory records, which generically report ‘calcium oxa-
late’ without more precision, thus lacking a clinically rele-
vant indication.
Physical methods reliably identify speciﬁc forms of
nephrolithiasis involving a single component such as
struvite, ammonium acid urate, cystine, 2,8-
dihydroxyadenine (DHA), xanthine or drugs, because in
this case, the chemical nature of the stones by itself deﬁnes
the type of renal stone disease. However, these cases are
infrequent, as they account for only 1e2% of the total in
Western countries, whereas in the case of common calcium
stones and, sometimes, of uric acid stones, simple identi-
ﬁcation of the chemical nature of stone constituents does
not provide full etiopathogenic information.
Because XRD or FTIR analysis is usually performed on
a powdered sample of the whole stone, no indication is
provided as to the respective location (in the core or
peripheral layers) of the diverse stone constituents in
common calcium oxalate or phosphate calculi, which
most often are of mixed composition, whereas the nature
of the core, the initial site of stone formation, may differ
from that of surrounding layers. In addition, the respec-
tive abundance and location of components are to be
considered in CaOx or CaP mixed stones made of several
crystalline phases such as COM, COD, carbapatite or
brushite.
Moreover, a same elemental composition such as CaOx
in the form of COM or COD as the main component may
correspond to very different etiopathogenic conditions,
each of which is reﬂected by a distinct morphology of both
the surface and section of calculi, thus emphasizing the
importance of morphological examination of stones in
complement to analysis of their composition.
Accordingly, we developed, since the early 1980s, a
comprehensive method of stone analysis termed morpho-
constitutional because it combines the morphologicalexamination of the surface and inner structure of the cal-
culus with constitutional analysis by FTIR, the term
constitutional encompassing the chemical nature, crystal-
line phases, relative proportions and location of the stones'
chemical components.2. The morpho-constitutional method of urinary
stone analysis
The method we adopted for the morpho-constitutional
stone analysis over the past four decades has been
described in detail elsewhere [2]. In short, the standardized
protocol comprises two steps:
- First, a morphologic examination by means of a ste-
reomicroscope (magniﬁcation 10e40) of the surface
and section of the calculus, with the identiﬁcation of
the nucleus (or core) and description of the inner or-
ganization, is carried out. The main points to be
recorded in each stone are size, form, color, aspect
(smooth, rough or spiky) of the surface, presence of a
papillary imprint (umbilication), presence of Randall's
plaque, aspect of the section (well organized with
concentric layers and/or radiating organization, or
poorly organized and loose structure) and location and
aspect of the nucleus.
- Thereafter, an analysis is performed by FTIR of a sample
of each part of the calculus (nucleus, mid-section and
surface), whenever allowed by the size of the stone,
and in all cases, the determination of the global pro-
portion of components in a powdered sample of the
whole stone.
Using this method, urinary stones could be classiﬁed
into 6 main morpho-constitutional types, themselves sub-
divided into a variable number of morphological subtypes,
each corresponding to a peculiar etiological or patho-
physiological condition. Indeed, the morphology of stones
is determined by a number of factors, such as the size and
shape of the constitutive crystals, the kinetics of stone
growth and the location of the ﬁrst steps of stone formation
within the urinary tract [3]. For example, uric acid and
struvite, which form large crystals and aggregates in urine,
lead to rapidly growing and poorly organized stones.
Conversely, COM stones, made of very small crystals, show
a dense and organized structure.
The kinetics of stone growth also inﬂuence the inner
structure of stones. Common COM calculi exhibit a well-
organized inner structure with concentric layers and
radiating crystallization, dark brown in color, which
suggests a slow stone growth due to intermittent peaks
M. Daudon et al. / C. R. Chimie 19 (2016) 1470e14911472of urinary oxalate concentration, whereas in primary
hyperoxalurias, the genetic disorder causes a heavy,
permanent overexcretion of oxalate ions, resulting in the
formation of calculi made of the same COM component
but with a very different, poorly organized inner struc-
ture and a different surface morphology and color.
Indeed, the dark-brown surface of common COM stones
results from the incorporation of pigments within the
stone during a slow lithogenic process, whereas in pri-
mary hyperoxalurias, the permanent deposit of freshly
produced COM crystals forms successive thin whitish
layers at the surface of stones [3,4].
Correlations between etiopathogenic conditions and the
corresponding morphological subtypes of CaOx, CaP and
uric acid stones, as well as of mixed stones made of these
components were established on the basis of more than
2000 stones analyzed at our laboratory, for which we had
full information on patient's history and comorbidity and
full evaluation of blood and urine chemistry.
We present below the morphologic characteristics and
associated etiopathogenic conditions of the various sub-
types of CaOX, CaP, uric acid and other purine stones, with
their respective prevalence among a total of 70,000 calculi
analyzed at our stone laboratory, located ﬁrst at Necker
Hospital (1985e2010)and now at Tenon Hospital. The main
structural characteristics of the stones included in the
morpho-constitutional classiﬁcation of urinary calculi are
summarized in Table 1.
3. Calcium oxalate stones
CaOx stones are divided into two types, according to
their predominant crystalline form, either COM (type I) or
COD (type II). Type I CaOx calculi present 5 morphologically
distinct aspects (types Ia to Ie), whereas type II calculi
present 3 morphologic aspects (types IIa to IIc). In our
experience, type I calculi account for about 20% of all stones
in France while type II calculi account for about 10%. Calculi
made of a mixture of COM and COD (mixed types IþII) are
as frequent as “pure” forms, as they represent nearly 20% of
all stones.
3.1. COM calculi (type I)
Fig. 1 depicts the subtypes of type I calculi with surface
and section morphologies and corresponding etiological
conditions. The common pathogenic factor of type I stones
is an elevated concentration of oxalate ions in urine
without a concomitant elevation of urinary calcium. The
degree and circadian duration of hyperoxaluria determine
the morphological aspect of the diverse subtypes (Ia to Ie).
3.1.1. Type Ia
Common, ‘idiopathic’ COM calculi present essentially as
type Ia, which represents 88% of the type I group and nearly
18% of all stones in our experience. They are typically
spherical, with a smooth, dark-brown surface and a section
showing compact concentric layers with a radiating orga-
nization starting from a nucleus. Such a structure is indic-
ative of intermittent deposition of COM crystals related topeaks of hyperoxaluria resulting from dietary habits. Three
conditions may be involved in the intermittent and mod-
erate excessive concentration of oxalate in urine: the most
common cause is a low water intake resulting in low
diuresis. Other dietary factors may be:
- a high consumption of oxalate-rich foods like dark
chocolate, beetroots, spinach, rhubarb, sorrel, star fruit,
etc;
- a high consumption of hydroxyproline-rich foods that
induce a metabolic synthesis of oxalate by the liver;
- a low intake of calcium, resulting in an increased ab-
sorption of oxalate ions by the gut.
Of note, most Ia stones are dark-brown in color because
their growth is intermittent allowing urinary pigments to
be ﬁxed on the crystals. However, in some cases, the surface
of Ia stones exhibit a very thin and often incomplete white
layer made of very small COM crystals. Because the un-
derlying layers are dark-brown, the thin superﬁcial deposit
appears as a grayish ﬁlm, the signiﬁcance of which being a
new deposition of COM crystals as a result of a very recent
peak of hyperoxaluria (Fig. 2). Thus, dark-brown Ia stones
as shown in Fig. 1 may be considered as quiescent or
metabolically inactive. By contrast, grayish Ia stones are
discovered in an active stage.
A number of type Ia calculi exhibit an umbilication, i.e., a
small depression at the stone surface which is the footprint
of the tip of the papillawhere the CaOx calculus formed and
was initially attached, and containing a deposit of CaP
named Randall's plaque [5e7].
3.1.2. Types Ib and Id
The types Ib and Id of idiopathic COM calculi are much
less frequent as they represent respectively only 5.0 and
4.1% of the type I group in our experience (these pro-
portions may be different in other populations or coun-
tries). Type Ib calculi have a brown to dark-brown,
mammillary, rough surface with an unorganized section
and they never exhibit an umbilication. This aspect is
observed in conditions of moderate hyperoxaluria, stasis,
and/or progressive crystalline conversion from COD to
COM. Type Id calculi present a quite different morphology,
with a very smooth surface, beige or pale brown in color,
and a section showing thin concentric layers without ra-
diations. These calculi often are many, as they form in
conditions of stasis in conﬁned cavities such as a divertic-
ulum or hydronephrosis, their plane and smooth surface
resulting from rubbing against each other.
The other two subtypes of COM stones (Ic and Ie) are
very infrequent (less than 0.5% of cases), but of major
clinical relevance.
3.1.3. Type Ic
Type Ic COM stones are, in our experience, pathogno-
monic of primary hyperoxaluria type I (PH1), the most se-
vere of all forms of nephrolithiasis. Calculi are made of pure
COM, similar to a number of idiopathic CaOx stones, but
exhibit a very different, peculiar morphology characterized
by a pale, yellowish budding surface (without any
Table 1
Morpho-constitutional classiﬁcation of urinary calculi.
Type Main component Surface Section
Ia Whewellite Mammillary surface. Frequent umbilication
and Randall's plaque indicative of papillary
origin. Color: brown.
Section made of compact concentric layers
with a radiating organization. Color: brown.
Ib Whewellite Mammillary and rough surface. No
umbilication. Color: brown to dark brown.
Compact unorganized section. Sometimes,
the presence of gaps. Color: brown to dark
brown.
Ic Whewellite Budding surface. Light color, cream to pale
yellow-brown, sometimes whitish in
children.
Finely granular and poorly organized
section. Light color, cream to pale yellow-
brown.
Id Whewellite Smooth surface. Color: homogeneous, beige
or pale brown.
Compact section made of thin concentric
layers. Color: beige or pale brown.
Ie Whewellite Locally budding, mammillary or rough
surface. Color: often heterogeneous, pale
yellow-brown to brown.
Locally unorganized and loose structure,
locally more compact radiating structure.
Color: heterogeneous, pale yellow-brown
to brown.
IIa Weddellite Spiculated surface showing aggregated
bipyramidal crystals with right angles and
sharp edges. Color: pale yellow-brown.
Section showing loose radial crystallization.
Color: pale yellow-brown.
IIb Weddellite Spiculated surface showing aggregated
bipyramidal crystals with blunt angles and
ridges. Color: pale yellow-brown.
Section showing compact unorganized
crystallization. Color: pale yellow-brown.
IIc Weddellite Rough surface. Color: gray-beige to dark
yellow-brown.
Unorganized core with a diffuse concentric
compact structure at the periphery. Color:
gray-beige to dark yellow-brown.
IIIa Uric acid
anhydrous
Homogeneous smooth surface. Color:
homogeneous, typically orange, sometimes
cream, ochre or yellowish.
Homogeneous compact, concentric
structure with a radiating organization.
Color: typically orange.
IIIb Uric acid
dihydrate± uric
acid anhydrous
Heterogeneous embossed, rough and
porous surface. Heterogeneous color from
beige to browneorange.
Poorly organized section with frequent
porous areas. Color: orange.
IIIc Urate salts, including
ammonium
hydrogen urate
Homogeneous or slightly heterogeneous
rough and locally porous surface. Color:
homogeneous, cream to grayish.
Unorganized porous section. Color: whitish
to grayish.
IIId Ammonium
hydrogen urate
Heterogeneous embossed, rough and
porous surface. Heterogeneous color:
grayish to dark brown.
Section made of alternated layers, thick and
brownish or thin and grayish, locally
porous. Sometimes, locally purplish.
IVa1 Carbapatite Homogeneous rough surface. Color: whitish
to beige.
Section: poorly organized, or diffuse
concentric layers. Color: whitish to beige.
IVa2 Carbapatite Embossed and varnished surface with small
cracks. Glazed appearance. Color:
homogeneous, pale brown-yellow to pale
brown.
Section made of compact alternated layers,
thick brown-yellow and thin beige. Often,
multiple nuclei (from collecting duct
origin).
IVb Carbapatite þ other
calcium phosphates
(±struvite)
Heterogeneous, both embossed and rough
surface with conﬂuent superﬁcial deposits.
Heterogeneous color: cream to dark brown.
Section made of irregularly alternating
thick, whitish, and thin, brown-yellow
layers.
IVc Struvite Homogenous surface made of amalgamate
crystals with blunt angles and edges.
Section: crude radial crystallization. Color:
whitish.
IVd Brushite Finely rough or dappled surface. Color:
whitish to beige.
Radial crystallization with more or less
visible concentric layers. Color: whitish to
beige.
Va Cystine Rough surface. Color: yellowish. Section: poorly organized, sometimes a
radiating organization. Color: yellowish.
Vb Cystine Smooth surface. Color: homogeneous,
cream to yellowish.
Concentric layers at the periphery, an
unorganized core. Color: heterogeneous,
cream (periphery) to yellowish (core).
VIa Proteins Matrix soft calculi. Homogeneous surface.
Color: cream to pale brown.
Unorganized section. Color: cream to pale
brown.
VIb Proteins± drugs
or metabolic
compounds
Heterogeneous, irregularly rough surface.
Locally scaled. Color: dark brown to black.
Crude and diffuse foliated structure. Color:
dark brown to black. Other components
often present in these stones may alter the
structure and the color.
VIc Proteins þ whewellite Homogeneous, smooth surface with clefts
and scales. Color dark brown.
Sectionmade of a dark brown protein shield
surrounding a loose, unorganized light core
containing whewellite crystals mixed with
proteins.
VII Miscellaneous Various morphologies and colors according
to the stone composition (infrequent
purines and drugs).
Variable organization and color according
to the stone composition.
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Fig. 1. Main relations between type I stones and etiology.
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electron microscopy unequivocally conﬁrmed the distinct
crystalline structure of common-type idiopathic COM
calculi and that of PH1-associated COM calculi [4]. Thus, the
unexpected ﬁnding of a clear color in a stone made of pure
COM should immediately alert to the probability of a PH1
or, at least, of a condition associated with heavy hyper-
oxaluria. Type Ic account for less than 1% of type I stones.
3.1.4. Type Ie
Type Ie stones are also indicative of speciﬁc pathogenic
conditions associated with marked hyperoxaluria resulting
froman intestinal dysfunction of diverse origins. This ‘enteric
hyperoxaluria’ is observed in inﬂammatory bowel diseases,
especially after ileal resection for Crohn's disease, in childrenwith cystic ﬁbrosis with a severe pancreatic deﬁcit [8], and
after bariatric surgery suchas jejuno-ileal bypassorRoux-en-
Ygastrojejunal bypass,which sometimesmay result in heavy
hyperoxaluria [9e13]. Type Ie calculi exhibit a locally
budding, mammillary or rough brown-yellow pale surface,
and a heterogeneous structure, with a mixture of poorly
organized brown-yellow pale areas and of locally concentric
dark brown layers with a radiating organization. Type Ie
stones represent 2% of type I stones.
Of note, COM stones are not the unique form of stones
that may develop in patients with inﬂammatory intestinal
diseases or after intestinal surgery because stones may
develop several years after the causal injury and result from
different lithogenic factors [14]. Thus, in patients with past
or current intestinal pathology, the morpho-constitutional
Fig. 2. Examples of a grayish thin layer on the surface of type Ia stones.
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the lithogenic factors acting in individual patients and
guide the optimal therapeutic strategy.
Another pathological condition associated with the
formation of type Ie stones is type 2 diabetes. About 6% of
stones formed in diabetic patients exhibit such a
morphology [personal data], thus suggesting that hyper-
oxaluria is, at least in a subgroup of these patients, a
metabolic disorder associated with type 2 diabetes. In fact,
a recent paper pointed out hyperoxaluria as a risk factor for
stone disease in diabetic patients [15]. Various metabolic
pathways involving carbohydrates and polyols may be
entailed in the formation of metabolic precursors of oxalate
such as glyoxal or glyoxylate [16e18].3.2. COD calculi (type II)
Fig. 3 depicts the subtypes of type II calculi, surface and
section morphology and associated conditions. The com-
mon pathogenic factor of type II stones is an elevated
concentration of calcium ions in urine without marked
elevation of urinary oxalate.
3.2.1. Type IIa
Type IIa stones are the most commonly encountered, as
they represent 69% of COD stones in our experience. Type
IIa calculi have a yellow or light-brown prickly, spiculated
surface due to the presence of aggregated bipyramidal
crystals with sharp angles and edges. Their section shows a
loose radial crystallization. They are observed in patients
with idiopathic hypercalciuria.
3.2.2. Type IIb
Type IIb stones account for 30% of COD stones. They
have a yellow or light-brown surface with smooth, long
bipyramidal crystals, thus resembling small ‘desert roses’,and with a compact poorly organized crystalline section.
They form in patients with both idiopathic hypercalciuria
and moderate hyperoxaluria.
3.2.3. Type IIc
Type IIc stones are much less frequent (0.7% of COD
stones). They have a rough gray-beige to pale brown sur-
face, with a diffuse concentric structure at the periphery.
They are observed in patients with both hypercalciuria and
an obstructive anatomic anomaly with multiple stones
resulting from stasis conditions.
3.3. Mixed COM and COD stones
Fig. 4 depicts mixed CaOx stones made of a mixture of
types Ia and IIa or Ia and IIb. These mixed stones are nearly
as frequent as pure CaOx stones; as in our experience, they
account for 20.4% of the whole series as compared with
29.4% for ‘pure’ COM or COD stones [19]. They associate
large aggregates of COD and COM crystals in variable pro-
portions. They are observed in patients with both hyper-
calciuria and hyperoxaluria, most often of dietary origin.
Because the lithogenic process is intermittent, COD crystals
may partly convert to COM, the thermodynamically stable
phase of calcium oxalate (Fig. 4C and D) [20]. As a conse-
quence, the stone morphology may present with typical
aspects of COD crystals overlapped by COM crystals. In a
number of cases, these stones are initiated on carbapatite
Randall's plaque at the surface of the tip of papilla (Fig. 4B, E
and F). Of note, unlike COD, COM crystals bind speciﬁcally
to Randall's plaque apatite.
3.4. Calcium oxalate trihydrate (COT) or caoxite
Caoxite is the third crystalline form of calcium oxalate
identiﬁed in urinary calculi and crystals [21]. Similar to
Fig. 3. Main relations between type II stones and etiology.
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scarcity in urinary calculi suggests that other factors are
involved in its formation. Caoxite was observed in two very
different situations: (i) CaOx stones induced by a drug
prescribed for cardiovascular diseases [22] and (ii) CaOx
stones formed in patients with primary hyperoxaluria
[personal unpublished data]. In both cases, COT was mixed
with COM. From a thermodynamic point of view, caoxite is
a very instable form of calcium oxalate which spontane-
ously and rapidly converts to COM. In in vitro studies,
caoxite was shown to transform to COMwithin a few hours
[23]. Thus, the presence of caoxite in urinary calculi sug-
gests that it is stabilized in the urine of affected patients. As
suggested by Gardner et al. [24], anionic compounds of
urine are able to inhibit caoxite formation, especially when
they have a molecular weight above 13,000 Da. An imbal-
ance between the promoters of calcium oxalate formation
and macromolecules in urine may explain how caoxite
crystals are observed in urine. Of note, in patients who
experienced stone formationwhile on long-term treatment
with piridoxilate-containing drugs, only those receiving
Myocoril® exhibited caoxite crystals in urine or stones. The
drug was a combination of two molecules, piridoxilate and
pentaerythritol tetranitrate. By contrast, patients treated
with Glyo-6®, a drug containing only piridoxilate, produced
common whewellite calculi. The mechanism of stone for-
mation ﬁrst involved piridoxilate, an equimolar association
of pyridoxine with glyoxylate, the direct precursor of oxa-
late, explaining hyperoxaluria as the main driving force in
the urine of all affected patients, even if other metabolicfactors were sometimes present such as hypocitraturia or
hypercalciuria. In addition, an impairment of macromole-
cules by pentaerythritol tetranitrate could explain the
presence and stability of caoxite in patients receiving
Myocoril®.
4. Phosphate stones (type IV)
Stones having CaP as the main component, ie, contain-
ing at least 50% of CaP, account in our experience for 8.6% of
thewhole series and 21.7% of calcium stones. CaP stones are
a very heterogeneous group because of their multiple
crystalline forms (Fig. 5). At variance with CaOx stones,
phosphate stones are pH dependent [25] and they are also
calcium dependent [26]. Their common lithogenic factors
are a pH of more than 6 and hypercalciuria, both of diverse
degrees, resulting in diverse chemical compositions, crys-
talline phases and morphology.
The most common crystalline phases found in CaP
stones are carbapatite (carbonated apatite, often improp-
erly termed apatite) and brushite (dicalcium phosphate
dihydrate), respectively present as main components in
67% and 14% of phosphate stones, whereas struvite (mag-
nesium ammonium phosphate hexahydrate), amorphous
carbonated calcium phosphate (ACCP), octacalcium phos-
phate pentahydrate and whitlockite (mixed calcium and
magnesium phosphate) are less frequent. With exception
of brushite, which forms large crystals, all other phases of
calcium phosphates form tiny particles made of nano-
crystals less than 15 nm in size [7].
Fig. 4. Main relations between mixed types of calcium stones and etiology. Note the presence of scattered pale deposits of carbapatite in the stone section (H) or
alternated layers of carbapatite and weddellite in the section of another stone (J).
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4.1.1. Type IVa1
Common CaP stones (type IVa1) are mainly composed of
carbapatite, often admixed with small amounts of other
components such as COM or COD. These stones exhibit a
whitish, rough homogeneous surface and their section
shows a poorly organized structure, with loose concentric
layers of the same color as the surface (Fig. 5). Type IVa1
stones are mainly related to hypercalciuria and/or urinary
tract infection.
4.1.2. Type IVb
Phosphate stones made of carbapatite admixed with
some amounts of other calcium phosphates or struvite
exhibit a different morphology (type IVb), with a hetero-
geneous surface, both embossed and rough, of clear to dark
brown color. The section is made of alternate thick whitish
and thin brown-yellow layers. These calculi are suggestive
of past or latent urinary tract infection, especially if they
contain small amounts of ACCP, whitlockite or struvite,which are markers of urinary tract infection (UTI). As a
matter of fact, such phosphate stones are more frequent in
women, who experience UTI more frequently than men. In
some cases, these stones may be related to a minor defect
in tubular acidiﬁcation, or hypercalciuria, especially when
they also contain COD.4.2. Struvite stones
Stones made mainly of struvite (type IVc) account for
1.2% of the whole series and their incidence relentlessly
declined over the past decades in industrialized countries
[27]. Struvite stones exhibit a whitish surface, homoge-
neously made of aggregates of large crystals with blunt
angles and edges; the section shows a diffuse, loose radial
crystallization (Fig. 5). These stones unequivocally result
from UTI by urea-splitting microorganisms. Of note, the
presence of struvite, even in a small amount, is the feature
of UTI by urease producing bacteria. In our experience, we
found struvite in 7.2% of all stones analyzed in our
laboratory.
Fig. 5. Main relations between type IV stones and etiology.
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tubular acidosis
Certain carbapatite stones exhibit a quite distinct
morphology from that of common CaP stones, although
having the same chemical composition and similar spectra
on FTIR [28,29]. Therefore, we subdivided type IVa into two
subtypes in order to differentiate common-type carbapa-
tite stones (type IVa1) from this peculiar subset of carba-
patite stones (type IVa2) which in our series represents
11.5% of CaP stones.
Type IVa2 calculi exhibit a very peculiar morphology
characterized by a yellow-brown, smooth surface with a
glazed appearance and small cracks, and a section showing
irregularly arranged thin whitish and thick yellow-brown
concentric layers (Fig. 5). Scanning electron microscopy
conﬁrmed the verydifferent structure of types IVa1and IVa2.This type of CaP stones appears to be speciﬁcally
formed in the context of defective distal tubular acidiﬁ-
cation, as it was observed in our experience in 95% of
patients with congenital distal renal tubular acidosis
(dRTA) and in 65% of CaP stones from patients with
Sj€ogren's syndrome, and also in severe forms of medul-
lary sponge kidneys, which induce injury of collecting
ducts and localized acidiﬁcation defects. However, stone
formers suffering from Sj€ogren's syndrome may form
CaOx stones and mixed CaOxþCaP stones. The same is
true of the majority of patients with MSK, who often have
pleiomorphic stones (personal data).
Patients with dRTA have been shown to form calculi
predominantly made of carbapatite [30e32] and plugging
of Bellini's ducts with apatite crystals has been evidenced
in patients with dRTA [33]. An association between
Sj€ogren's syndrome, distal tubular acidosis and carbapatite
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tion as to the morphology of calculi.
4.4. Brushite stones (type IVd)
Stones mainly composed of brushite represent 1.3% of
the total series and 14.4% of CaP stones. Brushite calculi at
their initial stage exhibit large rod-shaped crystals, there-
after evolving toward slightly rough or resembling a cab-
bage, whitish or beige surface and a section showing radial
crystallization with locally concentric layers (Fig. 5).
Brushite stones are clearly both calcium dependent and pH
dependent [26,36] and are observed in patients with
marked hypercalciuria and a urinary pH above 6 (6.4 as a
mean in our series). Brushite nephrolithiasis usually pre-
sents as idiopathic, but interestingly, type IVd stones were
observed in at least 14% of patients with primary hyper-
parathyroidism [26].
The identiﬁcation of brushite among CaP stones is
meaningful because brushite stones, at variance with
common carbapatite stones, are resistant to ESWL and have
an especially high activity and recurrence rate [37,38].
4.5. The carbonation rate of carbapatite
The ratio of carbonate ðCO32Þ ions relative to phos-
phate ðPO43Þ ions, or carbonation rate (CR), in carbapatite
stones may be determined as the ratio of the intensity of
their respective n3 bands on FTIR spectroscopy. The high
carbonate content of struvite stones, induced by urease-
producing bacteria, is well established [39].
In carbapatite stones devoid of any struvite, we observed
a high CR (15%) in calculi containing predominantly car-
bapatite (type IV) associated with small amounts of ACCP, in
which scanning electron microscopy identiﬁed bacterial
imprints, either rod-like or round, at the surface of spher-
ules of carbapatite, suggestive of the past presence of bacilli
or cocci. As a conﬁrmation, a history of UTI was found in
these patients [40]. The possible implication of UTI in the
formation of CaP stones made of carbapatite without stru-
vite, including by non-urease producing enterobacteria such
as E coli, has been suggested in previous studies [41e44].
In contrast, a low CR (7% as a mean) was found in calculi
made of mixed carbapatite and COD, without ACCP and
bacterial imprints, in hypercalciuric patients devoid of a
history of UTI [40]. Thus, a low CR value (<10%) in carba-
patite stones suggests a metabolic origin without the
participation of UTI, whereas a high CR value (15%),
especially if associated with the presence of ACCP, strongly
suggests that UTI was involved in the lithogenic process.
4.6. Mixed CaOx and CaP stones
Stones composed of a mixture of CaOx (COD and/or
COM) and carbapatite (without struvite) are twice more
frequent than phosphate stones containing only CaP as the
main component. They accounted for 19.7% of the total
number of stones in our series, as compared to 8.2% for
stones having carbapatite as the main component. The
commonest forms of mixed phosphateeoxalate stones arestones exhibiting a dual morphology (IIaþIVa1 or
IIbþIVa1), which together accounted for 12% of the total
series (Fig. 4), and stones exhibiting a complex heteroge-
neous morphology (type IþIIþIV) which accounted for 6%
of the total series (Fig. 6). The dual morphology IIa/bþIVa1
is mainly related to hypercalciuric states, irrespective of
their origin. The carbapatite contentmay inﬂuence strongly
the inner structure of the stones. Commonly, when it is
below 20%, the stone morphology is mainly driven by the
poorly organized agglomerates of COD crystals with CaP
deposits in the spaces between crystal aggregates. Such a
morphology, named (IIaþIVa1)i (“i” for “inorganise”) is
shown in Fig. 4H. By contrast, a high carbapatite content
(20 carbapatite < 70%; these thresholds are not absolute
limits) commonly results in another organization, named
(IIaþIVa1)c (“c” for “concentrique”), characterized by
irregular and alternate layers of carbapatite and weddellite
as shown in Fig. 4J.
Mixed CaOx/CaP calculi most often present as idio-
pathic, in a context of both hypercalciuria and relatively
high urine pH [30,45]. However, they may also reﬂect
speciﬁc etiologies, particularly medullary sponge kidneys
(MSK) and, less frequently, primary hyperparathyroidism
[26,31,46].
In our series, nearly 60% of calculi from patients with
primary hyperparathyroidism exhibited a mixed IIþIVa
morphology, with carbapatite having a low (<10%)
carbonation rate. Some calculi also contained COM, but
never exhibited a type I morphology, whereas other stones
had COD (12%), carbapatite (12%) or brushite (14%) as the
main component. Interestingly, type IVd stones mainly
composed of brushite and mixed stones of IIþIV type
together account for more than 72% of stones associated
with primary hyperparathyroidism [46]. A predominant
content of CaP in stones produced by patients with primary
hyperparathyroidism has also been reported by other au-
thors [45,47,48] but without the mention of the diverse
composition and morphology of the calculi.
In patients with MSK, stones were most often composed
of CaOx (COM or COD) but also of CaP in the form of car-
bapatite of IVa1 morphology often admixed with COM or
COD, or of IVa2 morphology [29]. A same patient may
produce calculi of diverse CaOx or CaP composition, this
pleiomorphism being suggestive of MSK (Fig. 6).
In addition, phosphate stones may be produced in pa-
tients with rare hereditary monogenic diseases character-
ized by a urinary phosphate leak often associated with
hypercalciuria. These diseases affect the proximal tubule
such as Dent's disease (or X-linked hypercalciuric neph-
rolithiasis) and related syndromes [49e51], hereditary
hypophosphatemic rickets with hypercalciuria induced by
inactivating mutations of the proximal tubule sodium/
phosphate co-transporters [52e54], or mutations of genes
coding for paracellin 16 or 19, responsible for familial
hypercalciuria with hypomagnesemia and nephrocalci-
nosis (FHHNC) [55,56]. In hereditary hypophosphatemic
rickets resulting from mutations associated with increased
circulating levels of FGF23, which induce a marked phos-
phate leak, the palliative treatment of profound hypo-
phosphatemia with calcitriol adds hypercalciuria to
Fig. 6. Main relations between ternary mixed types, polymorphs of calcium-containing stones and etiology.
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stones [57,58]. In these diseases, nephrolithiasis is associ-
ated with nephrocalcinosis made of tubulo-interstitial de-
posits of CaP crystals in the renal parenchyma, which is the
revealing sign more frequently than nephrolithiasis, inas-
much as these diseases manifest early in life with marked,
symptomatic disorders of calcium-phosphate homeostasis.
4.7. Etiopathogenic orientations based on the morphology of
CaP stones
Identiﬁcation of the various subtypes of CaP stones
suggests etiopathogenic hypotheses that orient biochem-
ical and genetic investigations.Phosphate s
     IVa1     IVb    
  (CA) (CA+other CaP±Struvite)   
(1) ± COM/COD:        - elevated urine pH (> 6.3)  
-“idiopathic” (female patients)      - hypercalciuria (+COD)   
- inherited proximal       - history of UTI with    
     tubular defects         urea-splitting bacteria   
- hypercalciuria (+ COD)        (+ struvite or carbonation  
- primary HPT (+COD)         rate (CR) of CA >15%) 
- MSK (+ COM ± COD)        or non ureasic bacteria 
(2) ± WK/ACCP:         (+ WK and/or ACCP without 
- UTI with non-ureasic        struvite, and CR< 15%) 
   bacteria (CR < 15%) 
Common CaP stones 
(Carbapatite ≥ 50%) 
Fig. 7. Main relations between phosphate stones and etiology according to the
CA¼ carbapatite; COM¼ calcium oxalate monohydrate; COD¼ calcium oxalate dihy
tract infection; WK¼whitlockite; ACCP¼ amorphous carbonated calcium phosphaCaP stones having carbapatite (without any struvite) as
the main component (type IVa1) are observed in common
idiopathic CaP nephrolithiasis, mainly observed in women,
but also suggest the search for past or current UTI involving
non-urea-splitting bacteria especially if some amount of
whitlockite or ACCP is also present (Fig. 7) [40].
In patients with nephrocalcinosis, type IVa1 carbapatite
stones suggest a proximal tubulopathy such as Dent's dis-
ease or some form of hereditary hypophosphatemic rickets.
Stones predominantly composed of type IVa1 carbapatite
or of a mixture of CaOX and CaP (types IVa1þIIa or IIb)
(Fig. 4) are observed in half of the patients with primary
hyperparathyroidism, who also form type IVd (brushite)
stones in 15e20% of cases in our most recent evaluation.tones 
IVc     IVd         IVa2 
    (Struvite) (Brushite) (peculiar CA) 
UTI      - idiopathic             specific of 
 (urea-splitting    (   U Ca+   U pH)            distal tubular 
    bacteria)      - primary HPT               acidosis 
      - phosphate leak  (inherited or 
        acquired) 
Peculiar phosphate stones 
ir morphology and composition. Abbreviations: CaP¼ calcium phosphate;
drate; CR¼ carbonation rate; MSK¼medullary sponge kidney; UTI¼ urinary
te; U Ca¼ urinary calcium; U pH¼ urine pH.
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distal renal tubular acidosis of genetic origin (various forms
of hereditary dRTA) or associated with Sj€ogren's syndrome,
which may be revealed by nephrocalcinosis besides the
usual extrarenal symptoms such as eye or mucosa dryness
[29]. MSK with localized defects of distal tubular acidiﬁ-
cation is another cause of type IVa2 stones. Usually, in MSK,
other types of calculi are observed in the same patients in
addition to IVa2 stones.
4.8. The clinical relevance of minor stone component
identiﬁcation for etiological diagnosis
Identiﬁcation of the minor components associated with
carbapatite contributes to etiological diagnosis. Presence of
brushite, COD or octacalcium phosphate pentahydrate is
suggestive of hypercalciuria while ACCP or whitlockite
orient towards urinary tract infection. Mixtures of CA and
COM are common in MSK.
It is noteworthy that stones may stay for a long time
within the kidney and that successive pathological condi-
tions may participate in stone growth. Therefore, it is
clinically relevant to take into account the composition and
morphology of the different areas of the calculus. For
example, a stone containing more than 80% of COM with a
cross-section of type Ia morphology suggests moderate
hyperoxaluria of dietary origin as the driving force of the
lithogenic process, whereas a stone surface mainly
composed of a mixture of COD and CA (mixed type IIa-
þIVa1), is suggestive of a recent, new lithogenic condition,
such as primary hyperparathyroidism inducing
hypercalciuria.
5. Uric acid and urate stones (type III)
5.1. Common uric acid stones
Common uric acid (UA) stones present two distinct
morphologies (Fig. 8).
Type IIIa stones, mainly composed of anhydrous UA
exhibit a smooth, typically orange surface with a section
showing concentric layers with a radiating organization
around awell-deﬁned nucleus. They account for 1.6% of the
whole series and are mainly seen as bladder urolithiasis in
older men with benign prostate hypertrophy. Of note, the
typical orange color of uric acid calculi results from a
particular afﬁnity between uric acid crystals and a red
pigment naturally present in urine and named uricine [59].
However, due to a low content of uricine in urine or
because of a poor adsorption of the pigment at the surface
of uric acid crystals, perhaps depending on urine pH, the
stone surface of uric acid calculi may appear moderately
colored and sometimes entirely whitish while inner layers
always exhibit some degree of pigmentation, ranging from
pale yellow to ochre.
Type IIIb calculi, predominantly made of UA dihydrate,
exhibit a rough and porous surface with a heterogeneous,
beige to orange color and an orange-red section with a
poorly organized, porous structure. Of note, because UA
dihydrate is unstable with time and spontaneously con-
verts to anhydrous UA, IIIb calculi initially formed as UAdihydrate may be composed mainly of anhydrous UA at the
time of analysis, although retaining a IIIb morphology.
Type IIIb calculi are the most frequently encountered as
they represent 77% of pure UA stones and they account for
7e8% of all stones. They are strongly pH dependent and
form in acidic urine (pH < 5.5) even in normouricosuric
patients [60], but more so if hyperuricosuria is present. This
type of UA stones is most often observed in patients with
gout, metabolic syndrome, or type 2 diabetes who have
both hyperuricosuria and acidic urine [61e63]. In these
patients, the low urinary pH reﬂects reduced ammonia
excretion resulting from insulin resistance, the common
metabolic disorder underlying these conditions [64]. UA
stones also are produced in cases of chronic hydro-
electrolytic diarrhea in patients with inﬂammatory bowel
diseases, especially after an ileostomy which results in a
heavy loss of water and bicarbonates and thus in a low-
volume urine with very low pH.
The association between type 2 diabetes and UA neph-
rolithiasis is two way. In our experience, UA stones were
three times more prevalent in type 2 diabetic stone formers
than in non-diabetics, whereas reciprocally prevalence of
type 2 diabetes was 2e3 times higher among UA than
calcium stone-formers [63,65]. Therefore, the onset of UA
nephrolithiasis in an adult patient should prompt a search
for latent type 2 diabetes, especially in the case of obesity.
5.2. Mixed uric acidecalcium oxalate stones
Mixed stones made of uric acid (type IIIb) and CaOx
(COM, type Ia) are not infrequent. They are observed in
patients, mostly obese and overeaters, who cumulate risk
factors of both uric acid and COM formation. This form of
mixed CaOx and UA nephrolithiasis is especially severe and
recurrent [66]. Fig. 9 illustrates various forms of these
associations.
5.3. Ammonium urate stones
Ammonium urate stones are very infrequent, as they
account for less than 0.4% of all calculi in our series. They
are still frequent in other parts of the world such as Africa
or South-East Asia [67] although their prevalence appears
to be decreasing in most of affected countries [68,69]. They
exhibit two different aspects.
Type IIIc stones have a rough and locally porous beige or
grayish surface, and an unorganized porous section of the
same color (Fig. 8). They are composed of various urate
salts, most often ammonium hydrogen urate, which is the
least soluble form of urates. They crystallize in urines of
very high pH (around 8) in the context of UTI with urea-
splitting bacteria which result in the local production of
ammonium ions from urea, and are mainly observed in
developing countries. In Western countries, they also may
result from excessive therapeutic urine alkalization.
Type IIId stones have a heterogeneously rough and
porous surface with a dark-brown color, and a section
showing alternatively thick, brown and thin, clear layers
with small porous zones (Fig. 8). They are predominantly or
totally made of ammonium hydrogen urate. Commonly,
they result from chronic diarrhea of infectious origins in
Fig. 8. Main relations between type III stones and etiology.
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ﬁbers (cereal) and low phosphorus (animal proteins)
consumption.
In Western countries, type IIId stones are observed in
the peculiar context of chronic laxative abuse, which in-
duces chronic occult diarrhea and high urinary ammonia
excretion, compensating for the diminished titratable
acidity in anorectic patients (mostly young women) with
very low protein, and thus a low phosphate intake. Such a
composition of stones is virtually speciﬁc of laxative abuse
[70]. In developing countries, type IIId calculi are mainly
found in children (mostly boys) with endemic bladder
urolithiasis [71]. Ammonium urate is still found as the
major component of the nucleus of stones in these coun-
tries, although urinary stones mainly composed of ammo-
nium urate have become infrequent [72].
Ammonium uratemay be admixedwith uric acid and/or
calcium oxalate, resulting in a heterogeneous morphology
(Fig. 10). In most cases, it is the mark of changes in risk
factors or diseases involved in stone formation. It is then
very important for diagnosis to consider successive layers
of the stone from the core to the surface. An example is
provided by the stone shown at the top of Fig. 10. The
photograph on the left side exhibits a typical IaþIIIb
structure which corresponds to a mixture of COM and uricacid. Such a ﬁnding is highly suggestive of a metabolic
syndrome with low urine pH and commonly normal uric
acid excretion and concentration. However, the section of
the stone (top right) displays a large poorly organized
grayish coremade of ammonium hydrogen urate (type IIIc).
This compound cannot be formed in very acidic urine as
does uric acid. In addition, ammonium urate crystallization
requires a high urate concentration. In our experience,
ammonium urate in the form of the IIIc morphology is
commonly observed in alkaline urine with a high ammo-
nium content as found in urinary tract infection by urea-
splitting bacteria. Thus, these conditions prompt to look
for another biochemical environment than that associated
with the metabolic syndrome. It is worth noting that the
intermediate layer of the stone is made of almost pure COM
in the form of type Ia. This part of the stone is a marker of
changes in urinary pH with time.
At the bottom of Fig. 10 (left), a mixed stone of type
IIaþIVa1 morphology corresponds to an association of
weddellite and carbapatite. It appears as a marker of
hypercalciuria. However, the section of the stone is het-
erogeneous (Fig. 10, right). The core is made of ammonium
hydrogen urate with a IIId morphology. In our experience,
such a morphological type is related to hyperuricosuria
associated with chronic diarrhea and hydro-electrolytic
Fig. 9. Main relations between mixed types of calcium oxalateeuric acid stones and etiology.
Fig. 10. Main relations between mixed types of calcium oxalate-uric acid-ammonium urate stones and etiology.
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intermediate layer suggests a transient episode of diarrhea
initiating the stone. Thereafter, ammonium urate was sur-
rounded by COM as a result of high oxalate concentration
mainly related to very low diuresis. Finally, the stone
growth was continued by the deposition of a mixture of
COD and carbapatite, suggestive of hypercalciuria. The
cause was a marked change in life style conditions anddietary habits of the patient who developed dietetic
hypercalciuria by excessive dairy product consumption.
6. Other stones
Infrequent stonesmade of cystine, proteins, rare purines
or drugs exhibit speciﬁc morphological types as observed
for common stones. However, in these types of
Fig. 11. Main relations between type V stones and etiology.
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mative than morphology, although, in some cases, stone
morphology may help to orient toward speciﬁc lithogenic
conditions.6.1. Cystine stones
Cystine calculi account for less than 1% of all stones and
they are usually made of pure cystine. Nevertheless, they
have two distinctive morphologies named type Va (the
most common one) and type Vb (Fig. 11). Type Va stones
are about ten times more frequent than type Vb stones.
Because basal medical treatment for the prevention of
cystine stones is urine alkalization, in 5e10% of patients
with recurrent stones, the presence of small proportions of
calcium phosphate, mainly in the form of carbapatite or
ACCP, may be observed within the new cystine stones
produced under medical treatment.6.2. Protein stones
Calculi mainly made of proteins are infrequent. They
may be encountered in three main clinical contexts: (i)
chronic pyelonephritis related to urinary tract infection; (ii)
proteinuria observed in glomerular kidney diseases, he-
maturia or crystal-induced bleeding; and (iii) end-stage
renal failure.
Chronic pyelonephritis may result in the formation of
soft matrices spreading into all kidney cavities, pyelons and
calices. The typical morphology of such soft calculi is type
VIa (Fig. 12). Of note, the stones are light-brown in color in
contrast with other types of protein-rich calculi.
Stones produced by patients with heavy proteinuria
and/or hematuria exhibit a very different aspect (type VIb),
as do soft matrices secondary mineralized by calcium and/
or magnesium phosphates in the case of infection stones.
Type VIb stones aremade of loose concentric protein sheets
often covered by crystals frommetabolic, infectious or drugorigin. The color and structure of the stone are inﬂuenced
by the compounds deposited on the protein sheets (Fig. 12).
Pure protein stones or, more often, mixed protein and
calcium oxalate stones, may be found in patients at end-
stage renal disease (ESRD) and are treated for several
months or years by maintenance dialysis. The stones are
commonly of small size (1e3 mm) and present with a
particular morphology (type VIc). They are made of unor-
ganized light agglomerates of whewellite and proteins
surrounded by a dark brown shell often composed of nearly
pure proteins (Fig. 12). These stones result from moderate
hyperoxalemia, defective reabsorption of small proteins in
the proximal tubule and supplementation with calcium
and vitamin D. It is a rare side effect of the long-term
management of ESRD patients [73].
6.3. Drug-containing stones
A limited number of drugs may induce urinary stone
formation [74]. Only molecules mainly excreted by the
kidney, poorly soluble in urine and administered at high
doses may crystallize in urine. Most of them belong to
antiseptic, antibiotic or antiviral families. In recent years,
the drugs most commonly responsible for stone formation
are atazanavir, indinavir, sulphonamides (mainly N-ace-
tylsulfadiazine) and calcium salt of ceftriaxone. Drugs may
form pure stones by themselves or theymay coat metabolic
calculi. In other cases, the drug may be admixed with
metabolic components such as calcium oxalate, calcium
phosphate or uric acid. Fig. 13 illustrates some examples of
drug-containing stones.
6.4. Drug-induced stones
A special attention should be paid to drug-induced
stones. Such calculi are made of common chemical phases
such as calcium oxalate, calcium phosphate or urate. They
result from the metabolic effects of some drugs in patients
treated for a long time by these drugs for chronic diseases.
Fig. 12. Main relations between type VI stones, high protein content and etiology.
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[74]. In some cases, the stone morphology may help to
suspect an unusual cause of lithogenesis. As discussed in
Section 3.4, an historical example was provided by the as-
sociation of piridoxilate and pentaerytritol tetranitrate that
was responsible for calcium oxalate stone formation in
patients receivingMyocoril® for severalmonths or years for
cardiovascular diseases. Unusual stone morphology due to
the presence of caoxite was one of the criteria used for the
detection of such etiology [21,22]. However, in most cases,
clinical inquiry is a major step for identifying long-term
treatments that could be involved in stone formation in a
given patient. Supplements of both vitamin D and calcium
were reported to increase the risk of calcium stone for-
mation [75e77] and dramatic epidemiological changes
with time in the lithogenesis of calcium oxalate from car-
bapatite Randall's plaque raise questions regarding the role
of vitamin D and calcium supplements [78,79]. Other drugs
may induce stone formation. It was reported several de-
cades ago that carbonic anhydrase inhibitors may induce
calcium phosphate stone formation [80]. More than 10% of
patients treated for a long term with acetazolamide or
topiramate for glaucoma or epilepsy develop calcium
phosphate stones [81,82]. Among other pharmacological
classes able to induce urinary stones, it was reported that
chronic laxative abuse may be responsible for ammonium
urate stone formation [70,83]. Finally, from an epidemio-
logical point of view, it was shown that urinary stones were
more frequent in men who ingest one gram or more of
ascorbic acid [84].
7. Clinical relevance of the morpho-constitutional
analysis of urinary stones
The morphological examination of urinary stones in
addition to chemical composition and identiﬁcation of the
crystalline phases of the chemical components deﬁned by
FTIR provide additional information of clinical relevance for
etiologic diagnosis and choice of the best therapeutic
strategy (Fig. 14). Obviously, stone analysis does not sub-
stitute for metabolic evaluation in stone formers. All pa-
tients should proﬁt from ametabolic investigation based on
the measurement of solutes in blood and 24 h-urine
collection to look for inherited or acquired diseases and for
risk factors for stone formation. Of note, in case no stone is
available for a morpho-constitutional analysis, a crys-
talluria study may be very useful in addition to a metabolic
evaluation.
7.1. The detection of hereditary stone diseases
One major interest is the rapid detection of severe
hereditary diseases that, if treated late or improperly,
may lead to a progressive impairment of renal function
and end-stage renal failure. Such a dramatic evolution is
usually due to late or erroneous diagnosis and is all the
more unfortunate since it might be prevented or sub-
stantially delayed by an appropriate treatment and since
these diseases are most often revealed by a stoneepisode. This aspect is to be especially emphasized with
regards to two hereditary diseases of particularly high
detrimental consequences:
- primary hyperoxaluria type 1 is the most severe of all
stone diseases because the permanent endogenous
oxalate overproduction leads tomassive hyperoxaluria,
recurrent COM nephrolithiasis and nephrocalcinosis
with a parenchymal deposit of COM crystals, decline in
GFR, hyperoxalemia with a systemic oxalosis, and ul-
timately end-stage renal disease requiring a combined
liverekidney transplantation [85,86]. Discovery of type
Ic calculi made of pure COM with an unexpected clear
color instead of the usual dark color of common-type
COM stones should immediately alert as to the prob-
ability of PH1 (or also PH2 and PH3), prompting an
early laboratory evaluation to achieve a deﬁnitive
diagnosis [4,86] and early institution of conservative
medical treatment, which starts by testing the effect of
pharmacological doses of pyridoxine, which diverts
glyoxylate metabolism and may substantially reduce
endogenous oxalate production [87,88].
- dihydroxyadeninuria, due to mutations of the
enzyme adenine phosphoribosyltransferase (APRT),
results in both the formation of stones made of 2,8-
DHA and inﬁltration of the renal parenchyma by
2,8-DHA crystals, leading to extensive interstitial
ﬁbrosis and ultimately to end-stage renal disease,
requiring chronic dialysis and kidney transplantation
[89e92]. The identiﬁcation of stones made of 2,8-DHA
by means of FTIR or XRD immediately orients the
diagnosis that will be conﬁrmed by the determination
of the enzymatic activity of APRT [93]. Considering
the small number of cases reported in various coun-
tries, it appears that APRT deﬁciency is an under-
estimated pathology [94], which is detrimental to the
patients because an early instituted, life-long phar-
macologic treatment with allopurinol or febuxostat
totally prevents the overproduction of DHA and its
clinical consequences. Of note, alkalization is totally
ineffective to treat DHA stones, at variance with uric
acid calculi, that may be misdiagnosed on the basis of
radiolucency in the absence of a proper stone anal-
ysis. As shown in Fig. 15, DHA stones have peculiar
morphologic characteristics, and thus may be differ-
entiated from UA calculi on stereomicroscopic ex-
amination in patients presenting with radiolucent
calculi [19]. The surface of the stones is often het-
erogeneous, embossed and locally rough. The color is
beige to rust-brown. A particular aspect of DHA
calculi is the local presence of small spherical de-
posits of pale rust-brown in color (black arrows in
Fig. 15) visible at the stone surface and also in the
cross-section. It is of prime importance for the affected
patients that an early diagnosis might be performed
on the basis of stone analysis or, if no stone is avail-
able, of microscopic examination of urine that con-
tains numerous typical crystals of dihydroxyadenine
[95].
Fig. 13. Morphological aspect of drug-containing stones.
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hyperoxaluria in common CaOx stone-formers
Among common CaOx calculi, the predominance of COD
type IIa suggests hypercalciuria as the main lithogenic
factor, and type IIb is suggestive of hypercalciuria associ-
ated with moderate hyperoxaluria. The predominance of
COM (type Ia) is most often associated with an increased
urine oxalate concentration resulting from poor liquid
intake and normal or moderately increased oxalateexcretion, often of dietary origin. In addition, type IIa or IIb
COD stones exhibiting at their surface dodecahedral crys-
tals instead of the usual octahedral (bipyramidal) crystals
are indicative of heavy hypercalciuria with urine Ca con-
centration often in excess of 10 mmol/l. Type IIa or IIb COD
calculi showing at their surface very large octahedral
crystals (commonly a length of crystal side 2.5 mm) were
found in our experience in patients with hypercalciuria
associated with additional lithogenic factors such as
hyperoxaluria and/or hypocitraturia (Fig. 16).
  Cystine     2,8-DHAd     AmUr     Xanthine        MUA    OPA       Drugs  Ic  Ie   IVa2 
Cystinuria dihydroxy-  * type IIId: xanthinuria long-term -pica   various    PH1 - enteric dRTA
adeninuria -laxative (inherited intake of -drugs (ex:ATZ PH2 hyperoxaluria (congenital 
     (APRT abuse, or acquired)  caffeine containing- IND  PH3     (COM stones)  or acquired)
deficiency) -endemic and Al- magnesium- EFV (COM - bariatric (CA stones)
bladder containing trisilicate NASD stones) surgery
    stones drugs or colloidal NASM) - diabetes type 2
    * type IIIc:     silica  CEFCa 
    - HU +       MT 
        U pH 
    (UTI or 
    therapeutic 
    alkalization) 
Peculiar morphology of CaOx 
or CaP stones 
Specific composition 
(identified by XRD or FTIR) 
Fig. 14. Contribution of morpho-constitutional analysis to the etiological diagnosis of rare stone diseases. Abbreviations: 2,8-DHAd¼ 2,8-dihydroxyadenine;
AmUr¼ ammonium hydrogen urate; MUA¼methyl-1 uric acid; OPA¼ opaline silica: PH¼ primary hyperoxaluria; dRTA¼ distal renal tubular acidosis;
APRT¼ adenine phosphoribosyltransferase; COM¼ calcium oxalate monohydrate; Al¼ aluminum; CA¼ carbapatite; ATZ¼ atazanavir; IND¼ indinavir;
EFV¼ efavirenz; NASD¼N-acetylsulfadiazine; NASM¼N-acetylsulfamethoxazole hydrochloride; CEFCa¼ ceftriaxone, calcium salt; MT¼ triamterene metabo-
lites; HU¼ hyperuricosuria; U pH¼ urine pH; UTI¼ urinary tract infection.
M. Daudon et al. / C. R. Chimie 19 (2016) 1470e14911488Spontaneously passed umbilicated type Ia calculi with
Randall's plaque made of carbapatite surrounded by COM
[7,79,96], either pure or admixed with COD (Figs. 4 and 6),
suggest a pathogenic role for hypercalciuria in the origin ofFig. 15. Morphological aspects of 2the stone [97,98]. Further changes in metabolic risk factors
may induce the coverage of the stone by other crystalline
phases such as uric acid in patients who develop insulin
resistance, metabolic syndrome and type 2 diabetes (Fig. 9).,8-dihydroxyadenine stones.
Fig. 16. Type IIa stones: relation between octahedral or dodecahedral crystals of weddellite and etiology.
M. Daudon et al. / C. R. Chimie 19 (2016) 1470e1491 1489In patients with inﬂammatory bowel diseases such as
Crohn's disease or pancreatic insufﬁciency, CaOx stones
often form as a consequence of absorptive hyperoxaluria.
However, in the early stages of such diseases, CaOx calculi
are commonly composed of COM or, less frequently of COM
and CODmixtures resembling common CaOx stones with a
type Ia or type IaþIIb morphology. At further stages of the
disease, especially in the case of ileal resection, changes in
stone morphology from type Ia to type Ie are progressively
observed in recurrent stone patients [99].7.3. Orientations given by the diverse types of CaP stones
In common CaP stones made predominantly of car-
bapatite type IVa1 or IVb, the presence of even small
amounts of struvite, ACCP or whitlockite and a high
carbonation rate (15%) of carbapatite are indicative of
past or current UTI [40]. Conversely, absence of these
compounds and a low rate of carbonation (<10%) are
indicative of CaP stones of metabolic origin such as in
primary hyperparathyroidism.
M. Daudon et al. / C. R. Chimie 19 (2016) 1470e14911490CaP stones of the IVa2 morphology are speciﬁc of distal
renal tubular acidosis [29], either congenital (complete or
incomplete) or acquired such as in patients with Sj€ogren
syndrome [3] and in some patients with MSK [29].
7.4. Orientations given by the diverse types of uric acid or
urate stones
Among uric acid stones, type IIIb calculi are frequently
associated with conditions of insulin resistance such as
obesity, metabolic syndrome and type 2 diabetes [100].
When occurring in overweight patients, they should
prompt an evaluation of glucose homeostasis.
In contrast with uric acid stones, urate calculi result
from hyperuricosuria and not from urine acidity. The
nature of the cation associated with the urate anion is
important to consider. Sodium hydrogen urate is associ-
ated with a high sodium concentration in the urine,
whereas ammonium hydrogen urate is associated with a
high urinary ammonium concentration, involving
different origins: metabolism, acid-base status, or UTI
with urease-producing microorganisms. Metabolism is
the natural origin of ammonium production as the kidney
excretes a major part of Hþ ions produced by the meta-
bolism in the form of ammonium ions. However, due to
the poor solubility of ammonium urate in alkaline urine,
patients presenting with hyperuricosuria may form
ammonium hydrogen urate when treated with alkali to
improve the solubility of uric acid. Ammonium urate
stones resulting from alkalizing treatment exhibit a type
IIIc morphology. The same type is encountered in the
case of local ammonium production by urea-splitting
bacteria. In patients suffering from chronic or intermit-
tent diarrhea related to enteric infections (endemic uro-
lithiasis) or to laxative abuse (in Western countries), the
loss of alkali and electrolytes by the gut results in the
overproduction of ammonium to reduce acidosis, defect
of electrolytes in urines, low diuresis and high urate
concentration, a combination of factors that favor the
crystallization of ammonium urate in the form of type
IIId stones. This morphology appears as a reliable marker
of such an etiology [101].
7.5. The prediction of response of stones to ESWL
The identiﬁcation of the crystalline phases of CaOx or
CaP stones is of major interest for predicting the proba-
bility of fragmentation by ESWL, inasmuch as imaging
techniques such as dual-energy X-ray absorption do not
afford totally reliable information [102,103]. Indeed,
common COM stones (type Ia) have a slightly higher
attenuation coefﬁcient (indicating a higher density on
computerized tomography) than COD stones [103]. COD
stones are easily fragmented whereas COM stones are
often resistant to fragmentation, depending on their in-
ternal crystal organization [104]. Among CaP stones, type
IVd calculi made of brushite have the highest density on
computerized tomography and are especially resistant to
ESWL. Cystine calculi, whenmodiﬁed by alkalization (type
Vb, or ‘smooth’), are less easily fragmented than native
‘rough’ cystine stones (type Va) [105]. Most medicaltreatments may modify some characteristics of cystine
crystals within stones [106], but usually fail to dissolve
them.
In conclusion, the morpho-constitutional analysis of
urinary stones which combines careful morphologic ex-
amination of the surface and section of stones with an
analysis of their composition by means of FTIR or XRD
considerably reﬁnes the etiologic diagnosis of kidney
stone disease. If identiﬁcation by these physical methods
of speciﬁc components such as cystine, 2,8-DHA,
xanthine, struvite, uric acid, ammonium hydrogen urate
or drugs is by itself sufﬁcient to identify the corre-
sponding types of nephrolithiasis, the simple mention of
calcium oxalate or calcium phosphate, as often only
provided in laboratory reports, does not provide the full
information that might be gained from a comprehensive
analysis. Indeed, despite a same chemical composition,
CaOx or CaP stones exhibit distinct morphologic charac-
teristics according to their etio-pathogenic factors. In
particular, the identiﬁcation of a peculiar, morphologic
aspect of COM calculus (Ic) orients towards the hypothesis
of primary hyperoxaluria, whereas a peculiar morphology
of carbapatite stones (IVa2) is speciﬁc of distal renal
tubular acidosis, either congenital or associated with ac-
quired diseases. Among common CaOx stones, distinction
between COM and COD as the main component orients
toward, respectively, hyperoxaluria (mainly of nutritional
origin) or hypercalciuria (due to high protein or salt
intake and genetic predisposition) as the preponderant
lithogenic factor. An FTIR analysis of the composition of
the core (or umbilication) of calculi indicates the initi-
ating lithogenic process whereas the surrounding layers
reﬂect factors acting in stone growth, that may differ from
those involved in the core composition. Thus, the pro-
posed morpho-constitutional method, which is simple,
rapid and cost-effective, appears to be the most infor-
mative method of stone analysis.References
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